ERBB2 and breast carcinoma: Orally taken ATP-competitive TKIs, such as the pan-HER-TKI neratinib, have garnered considerable attention in recent years as an effective extended adjuvant HER2-targeted therapy for patients with HER2-positive breast cancers after receiving a combination of chemotherapy and monoclonal antibody trastuzumab [9].